ARCHIVES

FDA Accepts DCT Board’s Criteria For Approval Of New Drugs, Explains Plan for Early Action

This article is from The Cancer Letter archive.

Vol. 15 No. 07 | February 17, 1989

Download PDF Visit The Full Archive

Related Articles

Phase II Study: Proton Therapy Can Have Similar Success Rate, Smaller Level of Risk in Treatment of Hodgkin Lymphoma

July 25, 2014

In Brief: Columbia’s Marks Reportedly Will Move To MSK; FDA Committee to Consider THC For Group C List

May 23, 1980

Adamson, Henney Chair Silicone Task Force

April 25, 1992

Recompetitions Of DCT Contracts Okayed

March 3, 1989

Stronger Measures Needed To Reduce Conflict of Interest, IOM Report Says

May 1, 2009

NCI, NIH Make Half-Hearted Pitch For Cancer Act Before Seemingly Uninterested Rogers Committee

March 10, 1978